Antipsychotic use tied to acute kidney injury, increasing pressure on nursing home reduction efforts


Older people who take antipsychotic medications are at a markedly increased risk of acute kidney injury, according to newly published research findings out of Canada. The study further supports ongoing efforts to reduce the number of nursing home residents on these drugs.

First-generation antipsychotic use correlated to hospitalization, study finds


Elderly patients taking antipsychotics should be carefully monitored, especially after they first start taking the medication, due to a higher risk of hospitalization, a new study finds.

Seroquel generics okay, appeals court says

AstraZeneca is not entitled to more exclusivity with its antischizophrenic medication, an appeals court agreed last week. The company had claimed its drug, Seroquel, deserved another three-year extension under the Food Drug and Cosmetic Act.

Reassessments, respect spark antipsychotic-reduction success, providers told


Reducing the number of residents with dementia who are on antipsychotics starts with reassessment, experts advised at this week's American College of Health Care Administrators convocation In Orlando. The key is a multi-step process providers can follow.

Seroquel maker to pay $5.5M in latest settlement related to off-label use of the antipsychotic drug


Drugmaker AstraZeneca recently settled a lawsuit with the state of Kentucky over allegations of improperly marketing its atypical antipsychotic drug Seroquel. Under the settlement, the London-based pharmaceutical company will pay the Bluegrass State $5.5 million.

Common antipsychotics dangerous for older adults, new study says

Common antipsychotics dangerous for older adults, new study says


Adding to the concerns about off-label use of antipsychotics, a new study has found four of the most common medications lack safety and effectiveness in older adults.

Physician defends use of antipsychotics for dementia patients in nursing homes

In response to a recent report from the Office of the Inspector General, a prominent psychiatrist is defending the practice of prescribing antipsychotic medications for nursing home residents with dementia.

AstraZeneca pays $68.5 million in Seroquel marketing case

Pharmaceutical giant AstraZeneca on Thursday agreed to pay $68.5 million to settle allegations that it inappropriately marketed the drug Seroquel for off-label uses, multiple states' authorities announced.

AstraZeneca settles for $520 million following investigation into improper marketing of anti-psychotic drug

Pharmaceutical giant AstraZeneca has agreed to pay $520 million to end a federal investigation into its alleged illegal marketing of the drug Seroquel for off-label uses, according to reports from Washington.